Abstracts Archive - Page 2171 of 2425 - ACR Meeting Abstracts

Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Nicola Dalbeth¹, Meaghan House², Gregory Gamble², Bregina Pool¹, Anne Horne², Lauren Purvis², Angela Stewart², Marilyn E. Merriman³, Murray Cadzow⁴, Amanda Phipps-Green³ and Tony R. Merriman³, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…
Abstract Number: 1176 • 2013 ACR/ARHP Annual Meeting
Pharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With End-Stage Renal Failure Receiving Hemodialysis
Anthony J. Bleyer¹, David E. Wright² and Alan Glicklich³, ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Savient Pharmaceuticals, Inc., San Diego, CA, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Among the estimated 8.3 million adults in the US with gout, approximately 40% have coexistent chronic kidney disease (CKD).1,2 Further, the presence of gout…
Abstract Number: 1177 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients
Prashanth Sunkureddi¹, Edith Toth², Jacques P. Brown³, Rüdiger Möricke⁴, Jan Michael Nebesky⁵, Gerhard Krammer⁵, Aiyang Tao⁶, Markus John⁵ and Alan Kivitz⁷, ¹Rheumatology, Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Canakinumab (CAN), a selective, fully human, monoclonal anti-IL-1β antibody has demonstrated long-term benefits in gouty arthritis (GA) patients (pts) by targeting the inflammatory pathway…
Abstract Number: 1178 • 2013 ACR/ARHP Annual Meeting
Effect Of Febuxostat On Serum Urate Levels In Gout Subjects With Hyperuricemia and Moderate-To-Severe Renal Impairment: A Randomized Controlled Trial
Kenneth G. Saag¹, Michael A. Becker², Andrew Whelton³, Patricia A. MacDonald⁴, Yun Zhou⁵ and Lhanoo Gunawardhana⁵, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Medicine, University of Chicago, Chicago, IL, ³The Johns Hopkins University and Universal Clinical Research Center, Inc., Baltimore, MD, ⁴Takeda Pharmaceuticals USA, Inc., Deerfield, IL, ⁵Takeda Global Research & Development Center, Inc., Deerfield, IL
Background/Purpose: Up to 20% of patients with hyperuricemia (serum urate [sUA] >6.8 mg/dL) and gout have moderate-to-severe renal impairment. Higher sUA (>8.5 mg/dL) may increase the…
Abstract Number: 1179 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study
Daria B. Crittenden¹, Jessica N. Kimmel¹, Virginia C. Pike¹, Daniel Diaz¹, Avni Shah², Cilian J. White¹, Michael DeBerardine², Grace Kim², Binita Shah³, Christopher J. Swearingen⁴, Jeffrey D. Greenberg⁵, Steven P. Sedlis³, Craig T. Tenner⁶, Bruce N. Cronstein¹ and Michael H. Pillinger², ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Gout patients are at increased cardiovascular (CV) risk. Since atherosclerosis is an inflammatory process, anti-inflammatory strategies to reduce CV risk are currently being investigated.…
Abstract Number: 1180 • 2013 ACR/ARHP Annual Meeting
Rising Burden Of Gout and Poor Management Of The Disease In The United Kingdom: A Nationwide Population Study
Chang-Fu Kuo^1,2, Michael Doherty³, Matthew J. Grainge⁴ and Weiya Zhang¹, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom, ⁴Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To describe the trends of epidemiology of gout and patterns of urate-lowering treatment in the UK general population from 1997-2012. Methods: We used the…
Abstract Number: 1181 • 2013 ACR/ARHP Annual Meeting
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
Kowoon Joo¹, Won Park¹, Seong-Ryul Kwon¹, Mie-Jin Lim¹, Kyong-Hee Jung¹, Hoyeon Joo¹ and Sung-Soo Kim², ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan Univ College of Medicine and Gangneung Asan Hospital, Gangneung, South Korea
Background/Purpose: We evaluated the effect of uric acid lowering therapy (ULT) in reducing the new development of comorbidities and the frequency of acute attacks…
Abstract Number: 1182 • 2013 ACR/ARHP Annual Meeting
The Performance Of a Diagnostic Rule For Acute Gouty Arthritis Without Joint Fluid Analysis: a Validation Study
Laura Kienhorst¹, Hein Janssens², Jaap Fransen³ and Matthijs Janssen¹, ¹Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: The gold standard to diagnose gout is the identification of monosodium urate (MSU) crystals in joint fluid. In primary care gout is mostly diagnosed…
Abstract Number: 1183 • 2013 ACR/ARHP Annual Meeting
The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
Stephen Juraschek¹, Lara Kovell², Edgar Miller III² and Allan C. Gelber³, ¹Department of Medicine, Johns Hopkins University, Baltimore, MD, ²Medicine, Johns Hopkins University, Baltimore, MD, ³Medicine/ Rheumatology, Johns Hopkins University, Baltimore, MD
The Treatment of Gout in Relation to the 2012 Uric Acid Target Guidelines in the US Population Background/Purpose: Gout is a debilitating form of arthritis mediated…
Abstract Number: 1184 • 2013 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Plays a Role In Gouty Arthritis
Kiwon Moon¹, Jinhyun Kim² and Yun Jong Lee³, ¹Internal medicine,, Kangwon National University Hospital, Chuncheon city, Kangwon province, South Korea, ²Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ³Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: High mobility group box 1 (HMGB1) is a crucial cytokine that mediated the response to infection, injury and inflammation. It is recently discovered that…
Abstract Number: 1185 • 2013 ACR/ARHP Annual Meeting
More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
Dinesh Khanna¹, Puja Khanna², Chris Storgard³, Scott Baumgartner⁴ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis, and its worldwide prevalence is increasing. EULAR and ACR guidelines recommend a target serum urate (sUA) ≤6 mg/dL.…
Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Jasvinder A. Singh¹, Chris Storgard², Scott Baumgartner³ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²4939 Directors Place, Ardea Bioscience, San Diego, CA, ³Ardea Biosciences, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…
Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Michael A. Becker¹, David Fitz-Patrick², Chris Storgard³, Matt Cravets⁴ and Scott Baumgartner⁵, ¹Medicine, University of Chicago, Chicago, IL, ²East-West Medical Research Institute, Honolulu, HI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Ardea Biosciences, San Diego, CA
Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…
Abstract Number: 1188 • 2013 ACR/ARHP Annual Meeting
An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy
John D. Carter¹, Michelle Patelli², Scott Anderson², Neelish Prakash², Robyn Aydelott², Ernesto Rodriguez², Helen E. Bateman³, Ashley G. Sterrett⁴, Joanne Valeriano-Marcet⁵ and Louis R. Ricca⁶, ¹Internal Medicine; Division of Rheumatology, University of South Florida, Tampa, FL, ²University of South Florida, Tampa, FL, ³Medicine / Rheumatology (111K), James A Haley VA Hospital USF, Tampa, FL, ⁴Internal Medicine/Rheumatology, JAHVA, Tampa, FL, ⁵Internal Medicine, University of South Florida, Tampa, FL, ⁶University of South Florida College of Medicine, St Petersburg, FL
Background/Purpose: We recently demonstrated that synovitis is present in the vast majority of patients with inter-critical gout and that the severity of this synovitis did…
Abstract Number: 1189 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study
Scott Baumgartner¹, Hyon Choi^2,3, Nicola Dalbeth⁴, David Fitz-Patrick⁵, Matt Cravets⁶ and Chris Storgard⁷, ¹Ardea Biosciences, San Diego, CA, ²Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Auckland District Health Board, Auckland, New Zealand, ⁵East-West Medical Research Institute, Honolulu, HI, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷4939 Directors Place, Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the first-line urate-lowering therapy (ULT) for most people with gout, but target serum uric acid (sUA) levels of 200-300 >300-400 >400-500 >500-600…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].